The first stop for professional medicines advice

Supply

46 results

Applied filters

Prescribing available HRT products

28 April 2022Hormone Replacement Therapy availability varies currently. Check for available products and keep up-to-date. Supply content is maintained regularly by DHSC.

Prescribing and using thiamine to prevent refeeding syndrome

2 May 2024Intravenous thiamine for prevention of refeeding syndrome should be reserved for those with intestinal failure where the oral or enteral route is unavailable.

Prescribing and switching between modified-release methylphenidate

16 November 2023Modified-release methylphenidate capsules and tablets differ. Ensure patients receive appropriate treatment, particularly during periods of supply disruption.

Prescribing and ordering available pancreatic enzyme replacement therapies

17 July 2024The availability of pancreatic enzyme replacement therapies (PERTs) varies currently. Use our resources and mini-tool to find matches for licensed products.

Prescribing GLP-1 receptor agonists

28 June 2023Glucagon-like peptide-1 (GLP-1) receptor agonist availability is resolved. Supply content is maintained by DHSC.

Patient Group Directions (PGDs) and abortifacients

14 September 2020This article advises on the legal position on the supply/administration of abortifacients under PGDs.

Patient Group Direction use in End of Life Care

10 August 2020Considerations required before implementing Patient Group Directions (PGDs) in End of Life Care.

Outsourcing of Storage or Preparation of ATIMPs Across Legal Boundaries

15 November 2022Guidance on the considerations for Pharmacy Clinical Trial Sites outsourcing activities involved in the delivery of ATIMPs

Operational Implications of UK Exit from the EU for NHS Clinical Trial Sites

16 September 2022A summary of the implications of the UKs exit from the EU for clinical trial sites for both IMP and ATIMPs, including supply to and from Northern Ireland

Offender healthcare settings and transcribing

28 January 2025Consideration needs to be given to the risk factors particularly associated with transcribing in offender healthcare settings